Home
ICAPS Cohorts
- ACCORD
- ACEi-SS
- ALLHAT/GENHAT
- ASCOT
- BB-SS
- CHARGE
- CHIEF
- CSN-stayondiur
- Estonia Biobank
- FEVER-PGx
- GENRES
- GERA 1
- GERA 2
- GoDARTS
- GoShare
- GS-SFHS
- HARP
- IDEAL
- INMEGEN-PHEM
- INVEST
- LIFELINES
- MESA
- MIHYPHCTZ
- NORDIL
- PEAR 1
- PEAR 2
- PHSS
- SDS
- SOPHIA
- SPS3
- TAICHI
- UCP
Members Only
My Profile
Join ICAPS
ICAPS Publications

Connect with us

Facebook
YouTube
Twitter

Text-only version of this website
Skip navigation
Home page
What's new
Search
Contact Webmaster
Website policies
Disability services

None

ICAPS

International Consortium for Antihypertensives Pharmacogenomics Studies

Log in

Home
Home
ICAPS Cohorts
- ACCORD
- ACEi-SS
- ALLHAT/GENHAT
- ASCOT
- BB-SS
- CHARGE
- CHIEF
- CSN-stayondiur
- Estonia Biobank
- FEVER-PGx
- GENRES
- GERA 1
- GERA 2
- GoDARTS
- GoShare
- GS-SFHS
- HARP
- IDEAL
- INMEGEN-PHEM
- INVEST
- LIFELINES
- MESA
- MIHYPHCTZ
- NORDIL
- PEAR 1
- PEAR 2
- PHSS
- SDS
- SOPHIA
- SPS3
- TAICHI
- UCP
Members Only
My Profile
Join ICAPS
ICAPS Publications

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.

Published: February 27th, 2015

Category: FEVER-PGx Publications

Recent Publications

Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide

Personalized Therapy of Hypertension: the Past and the Future

PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.

Publication Archive

Publication Archive

Log in
Updated February 27, 2015
Contact Webmaster

ICAPS GROUP